Paroxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI) and anxiolytic that is approved to treat numerous mood disorders. Serotonin syndrome, defined as a triad of mental status changes, autonomic instability, and neuromuscular abnormalities, is a potentially life-threatening complication of administering such serotonin-modifying drugs. Most cases of serotonin syndrome that have occurred with paroxetine administration are due to inadvertent drug interactions, most notably between SSRIs and monamine oxidase inhibitors, or intentional overdoses. The authors present the case of an 80-year-old woman who presented with serotonin syndrome while on a therapeutic dose of paroxetine. Paroxetine was stopped, and aggressive hydration with fluids and treatment with cyproheptadine was followed by remarkable improvement and return to baseline status in 4 days. This case illustrates the importance for physicians to have a heightened sense of suspicion of the serotonin syndrome in any patient known to be on serotonin-modifying agents presenting with altered sensorium and cholinergic symptoms. Consequently, they will be able to start timely treatment without subjecting the patient to unnecessary and potentially harmful tests.
BackgroundParoxetine (Paxil) is a selective serotonin reuptake inhibitor (SSRI), FDA approved for the treatment of panic disorder, depression, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder, OCD, and premenstrual dysphoric disorder. Its efficacy is linked to potentiation of serotoninergic activity in the central nervous system resulting from inhibition of neuronal reuptake of serotonin (5-hydroxytryptamine, 5-HT). A dreaded iatrogenic complication of administering Paxil and other SSRIs is the serotonin syndrome. It has normally been reported to have occurred with concomitant administration of MAOIs and SSRIs or in significant overdose of SSRI. It has rarely been reported with therapeutic doses of paroxetine. Only one other case was found in our research.Case ReportWe present a case of an 80-year-old Russian female who presented with altered mental status, myoclonus, and rhabdomyolysis. Her medical history was significant for major depression treated with paroxetine for thr last 6 months. After ruling out infectious, metabolic, cerebrovascular, and cardiac causes for her change in mentation, we diagnosed her with serotonin syndrome due to the administration of paroxetine, albeit at therapeutic doses. After immediately discontinuing the offending drug, the patient was aggressively hydrated with fluids and treated with an antiserotoninergic agent, cyprohepatidine. She responded to the cyproheptadine and fully recovered by day 3 of admission.DiscussionThe serotonin syndrome is an iatrogenic complication of proserotoninergic drugs comprising of at least three signs and symptoms reflecting mental status changes, autonomic instability, and neuromuscular abnormalities. As the exposure to proserotoninergic drugs is increasing, so is the incidence of the serotonin syndrome. Our research shows that the syndrome has mainly occurred in conjunction with overdoses, drug interactions such as concomintant use of MAOIs or neuroleptics, and in pediatric populations. However, we report a case where the syndrome occurred in a patient who was taking paroxetine routinely at therapeutic doses.ConclusionIt is important to suspect this potentially lethal and possibly reversible cause in any patient that presents acutely with mental status changes and is known to be on proserotoninergic drugs regardless of duration and dosage. Early suspicion would help the patient's prognosis while also preempting numerous diagnostic tests and possibly harmful treatments. Although the reported incidence of serotonin syndrome is 0.4/1,000, its actual incidence might be underestimated due to lack of clinical suspicion and diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.